Stocks Analysis: Bristol-Myers Squibb
Image Source: Pixabay
Founded in 1887 and headquartered in Princeton, NJ Bristol-Myers Squibb (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.
The company was formerly known as Bristol-Myers Company.
Three key data points gauge Bristol-Myers Squibb or any dividend paying entity, namely:
(1) Price
(2) Dividends
(3) Returns
Those keys also show if any company has made, is making, and will make money.
BMY Price
BMY’s price rose about 6.2% for the year as of Friday’s closing market price, growing from $44.03to $46.75.
BMY Dividends
BMY has paid variable quarterly dividends since February, 1986. The current forward looking annual dividend of $2.48 yields 5.30% per Friday’s closing market price.
BMY Returns
Putting it all together, a $12.73 estimated gross gain per share shows up.
Add BMY’s annual $2.48 dividend to an estimated $10.25 annual price gain, to total that $12.73 gross gain amount.
A little under $1000 invested at the recent $46.75 price would buy 21 shares which, multiplies the $12.73 gross gain to $267.33.
Furthermore, about one-fifth of that gain comes from the $53.00 in dividends generated from a $1,000 investment. The $53.00 amounts to about $6.254 more than the recent $46.75 single-share price.
(A dividend dogcatcher rule is to never buy a dividend from $1000 invested that pays less than the cost of a single share.)
Therefore, you may choose to pounce on Bristol-Myers Squibb and its 5.3% dividend yield along with its 39 year dividend record.
The exact track of BMY’s future prices and dividends will entirely be determined by market action and company finances.
Remember the best way to track stock performance and dividend payments is through direct ownership of company shares.
More By This Author:
Stock Analysis: Traton
Stock Analysis: Tokyo Century
Stock Analysis: Sanwa Holdings
Disclaimer: This article is for informational and educational purposes only and should not be construed to constitute investment advice. Nothing contained herein shall constitute a ...
more